Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc.
Astellas Pharma Inc
Sanofi
Sanofi
Gilead Sciences
Gilead Sciences
Hoffmann-La Roche
Kartos Therapeutics, Inc.
CicloMed LLC
Kronos Bio
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Philogen S.p.A.
Cornerstone Pharmaceuticals
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hoffmann-La Roche
Bristol-Myers Squibb
Gilead Sciences
Polaris Group
Pfizer
Nohla Therapeutics, Inc.
Viron Therapeutics Inc
PharmaMar
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Hoffmann-La Roche
Texas Oncology Cancer Center
Ascenta Therapeutics
Antisoma Research